ADMA Biologics is a biopharmaceutical and immunoglobulin company that manufactures, markets and develops plasma-derived biologics for the treatment of immune deficiencies and the prevention and treatment of certain infectious diseases. The company's marketed products consist of: Nabi-HB, which is indicated for the treatment of acute exposure to blood containing Hepatitis B surface antigen; and Bivigam, which is indicated for the treatment of primary humoral immunodeficiency. The company is also developing a pipeline of plasma-derived therapeutics, including its key pipeline product candidate, RI-002, for the treatment of Primary Immune Deficiency Disease.

America's Car-Mart is an automotive retailer focused on the Integrated Auto Sales and Finance segment of the used car market. The company's operations are principally conducted through its two operating subsidiaries, America's Car Mart, Inc. and Colonial Auto Finance, Inc. The company primarily sells older model used vehicles and provides financing for substantially all of its customers. The company purchases vehicles primarily from wholesalers, new car dealers, individuals and auctions. The company provides financing to substantially all of its customers who purchase a vehicle at one of its dealerships. A majority of the company's customers make their payments in person at the dealership where they purchased their vehicle.

Asbury Automotive Group is a holding company. Through its subsidiaries, the company is an automotive retailer. The company's stores provide automotive products and services, including new and used vehicles; parts and service, including vehicle repair and maintenance services, replacement parts and collision repair services; and finance and insurance products, including arranging vehicle financing through third parties and aftermarket products, such as extended service contracts, guaranteed asset protection debt cancellation, prepaid maintenance, and credit life and disability insurance. The company's new vehicle franchise retail network is made up of dealerships operating under locally-branded dealership groups.

AutoNation, through its subsidiaries, is an automotive retailer. The company provides a range of automotive products and services, including new vehicles, used vehicles, parts and service, which includes automotive repair and maintenance services as well as wholesale parts and collision businesses, and automotive finance and insurance products, which include vehicle service and other protection products, and the arranging of financing for vehicle purchases through third-party finance sources. The company owns and operates new vehicle franchises from stores located in the United States, in main metropolitan markets in the Sunbelt region. The company has three segments: Domestic, Import, and Premium Luxury.

AutoZone is a retailer and a distributor of automotive replacement parts and accessories. The company operates stores in the United States, including Puerto Rico and Saint Thomas, Mexico, and Brazil. Each store carries a product line for cars, sport utility vehicles, vans and light trucks, including new and remanufactured automotive hard parts, maintenance items, accessories and non-automotive products. In addition, the company has a commercial sales program that provides commercial credit and delivery of parts and other products to local, regional and national repair garages, dealers, service stations and public sector accounts. The company also sells the ALLDATA brand automotive diagnostic and repair software.

Bellus Health is engaged in the research, development and commercialization of products for health solutions. Co.'s principal business activity has been the development of its core technology platform, amyloid inhibitors, which focuses on chemical compounds that could have the potential to inhibit the formation, deposition and toxicity of amyloid fibrils which are implicated or believed to be the underlying causes of certain diseases. The diseases targeted by Co. include Amyloid A (AA) amyloidosis as well as Alzheimer's disease. KIACTA™ is being developed to treat AA amyloidosis meanwhile NRM8499, prodrug of tramiprosate is being developed to treat Alzheimer's disease.

Celldex Therapeutics is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company has four drug candidates in clinical development, including CDX-1140, an agonist human monoclonal antibody targeted to CD40, a key activator of immune response; CDX-3379, a human monoclonal antibody designed to block the activity of ErbB3; varlilumab, an immune modulating antibody targeting CD27 designed to improve a patient's immune response; and CDX-301, a dendritic cell growth factor.

Genuine Parts is engaged in the distribution of automotive replacement parts, industrial parts, and business products. The company's reportable business segments are: Automotive, which distributes automotive parts and accessory items and provides inventory, cataloging, marketing, training and other programs to the automotive aftermarket; Industrial, which distributes industrial replacement parts and related supplies such as bearings, mechanical and electrical power transmission products, industrial automation, and hose, among others; and Business Products, which is engaged in the wholesale distribution of a line of office and other business-related products through a customer base of resellers.

Geron is a biopharmaceutical company that is focused on the development and commercialization of imetelstat, a therapeutic for hematologic myeloid malignancies. The company has global rights to imetelstat, a telomerase inhibitor, which was discovered and developed at the company Imetelstat has been granted both Orphan Drug and Fast Track designations by the United States Food and Drug Administration, for the treatment of patients with Low or Intermediate-1 risk myelodysplastic syndromes (MDS), or lower risk MDS, and for the treatment of patients with Intermediate-2 or High-risk MF relapsed after or refractory to janus kinase inhibitor treatment, or relapsed/refractory myelofibrosis.

Lakes Oil is engaged in hydrocarbon exploration and investment. Co. has two reportable segments. Co.'s first segment is engaged in the exploration for hydrocarbon reserves, principally in on-shore regions of Victoria, Australia. Co.'s second segment is engaged in the investment in entities engaged in exploration for energy reserves.

Mirum Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company's pipeline consists of two clinical-stage product candidates, maralixibat and volixibat, with mechanisms of action that have potential utility across a wide range of orphan liver diseases.

Monro is engaged principally in providing automotive undercar repair and tire sales and services. The company provides a range of services on passenger cars, light trucks and vans for brakes; mufflers and exhaust systems; and steering, drive train, suspension and wheel alignment. The company also provides other products and services, including tires and routine maintenance services, including state inspections. The company focuses on the repair and replacement of parts which periodically replaced as they wear out. The company does not perform under-the-hood repair services except for oil change services, various flush and fill services and some minor tune-up services.

O'Reilly Automotive is a retailer of automotive aftermarket parts, tools, supplies, equipment and accessories, selling its products to both do-it-yourself and service provider customers. The company's stores carry a product line, including: new and remanufactured automotive hard parts and maintenance items, such as alternators, batteries, brake system components, belts, chassis parts, driveline parts, engine parts, fuel pumps, hoses, starters, temperature control, water pumps, antifreeze, appearance products, engine additives, filters, fluids, lighting, oil and wiper blades; and accessories, such as floor mats, seat covers and truck accessories.

Penske Automotive Group is a transportation services company that operates automotive and commercial truck dealerships and distributes commercial vehicles, diesel engines, gas engines, power systems and related parts and services. The company has four segments: Retail Automotive, consisting of its retail automotive dealership operations; Retail Commercial Truck, consisting of its retail commercial truck dealership operations in the United States and Canada; Other, consisting of its commercial vehicle and power systems distribution operations and other non-automotive consolidated operations; and Non-Automotive Investments, consisting of its equity method investments in non-automotive operations.

RAPT Therapeutics is a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. The company is engaged in developing highly selective small molecules designed to modulate the critical immune responses underlying these diseases by utilizing its proprietary drug discovery and development engine. The company's oncology drug candidate, FLX475, inhibits the migration of immunosuppressive regulatory T cells into tumors. The company's inflammation drug candidate, RPT193, inhibits the migration of type 2 T helper cells, into allergically-inflamed tissues.

SIGA Technologies is a commercial-stage pharmaceutical company focused on the health security market. Health security comprises countermeasures for biological, chemical, radiological and nuclear attacks, vaccines and therapies for emerging infectious diseases, and health preparedness. The company's primary product is an oral formulation of TPOXX?, an antiviral drug for the treatment of human smallpox disease caused by variola virus. The United States Food and Drug Administration has approved oral TPOXX? for the treatment of smallpox.

Sonic Automotive is an automotive retailer in the United States. The company has two reportable segments: the Franchised Dealerships Segment and the EchoPark Segment. The Franchised Dealerships segment is comprised of retail automotive franchises that sell new vehicles and buy and sell used vehicles, sell replacement parts, perform vehicle maintenance, warranty and repair services, and arrange finance and insurance products. The EchoPark segment is comprised of pre-owned vehicle retail locations that provide customers an opportunity to search the company's nationwide inventory, purchase a pre-owned vehicle, select finance and insurance products and sell their vehicle to the company

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company developing a pipeline of cancer therapies. The company's primary product candidate, entinostat is a once-weekly, oral, small molecule, Class I HDAC inhibitor, which is being evaluated in the Phase 3 E2112 registrational clinical trial in combination with exemestane for hormone receptor positive, human epidermal growth factor receptor 2 negative, breast cancer, an indication for which entinostat has been granted therapy designation from the United States Food and Drug Administration. SNDX-5613, the company's clinical-stage product candidate, is a small molecule inhibitor of the interaction of menin with the mixed lineage leukemia protein.

Tricida is a pharmaceutical company focused on the development and commercialization of its drug candidate, TRC101 (veverimer), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis by binding and removing acid from the gastrointestinal tract.